Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.605 |
|---|---|
| High | 0.6779 |
| Low | 0.590 |
| Bid | 0.6336 |
| Offer | 0.68 |
| Previous close | 0.595 |
| Average volume | 88.70k |
|---|---|
| Shares outstanding | 7.14m |
| Free float | 7.09m |
| P/E (TTM) | -- |
| Market cap | 4.25m USD |
| EPS (TTM) | -3.60 USD |
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.
More ▼
- Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
- Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting
- Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH
- Galmed Issues CEO Letter to Shareholders
- Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
- Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine
- Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro
More ▼
